Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint-Reference-Cited by-同舟云学术

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

Published:2018-08-17 Issue:1 Volume:4 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Boughey Judy C., ,Alvarado Michael D.,Lancaster Rachael B.,Fraser Symmans W.,Mukhtar Rita,Wong Jasmine M.,Ewing Cheryl A.,Potter David A.,Tuttle Todd M.,Hieken Tina J.,Carter Jodi M.,Jakub James W.,Kaplan Henry G.,Buchanan Claire L.,Jaskowiak Nora T.,Sattar Husain A.,Mueller Jeffrey,Nanda Rita,Isaacs Claudine J.,Pohlmann Paula R.^ORCID,Lynce Filipa,Tousimis Eleni A.,Zeck Jay C.,Lee M. Catherine,Lang Julie E.^ORCID,Mhawech-Fauceglia Paulette,Rao Roshni,Taback Bret,Godellas Constantine,Chen Margaret,Kalinsky Kevin M.,Hibshoosh Hanina,Killelea Brigid,Sanft Tara,Hirst Gillian L.^ORCID,Asare Smita,Matthews Jeffrey B.,Perlmutter Jane,Esserman Laura J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/s41523-018-0074-6.pdf

Reference21 articles.

1. Prowell, T. M. & Pazdur, R. Pathological complete response and accelerated drug approval in early breast cancer. N. Engl. J. Med. 366, 2438–2441 (2012).

2. Cortazar, P., Zhang, L. & Untch, M. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172 (2014).

3. Krag, D. N. et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8, 881–888 (2007).

4. Goyal, A., Newcombe, R. G., Chhabra, A. & Mansel, R. E., ALMANAC Trialists. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer–results of the ALMANAC validation phase. Breast Cancer Res. Treat. 99, 203–208 (2006).

5. Veronesi, U. et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 349, 546–553 (2003).

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial;Annals of Surgical Oncology;2024-07-12

2. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations;Cancer;2024-07-10

3. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry;European Journal of Surgical Oncology;2024-04

4. Immunotherapy in Breast Cancer;The Basics of Cancer Immunotherapy;2024

5. Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial;Annals of Surgical Oncology;2023-06-28